News Archive

In response to the COVID-19 pandemic, the POP02 study has expanded its protocol to include antiviral drugs that could be used to treat pediatric patients with COVID-19.

A paper authored by the DCRI’s Adrian Hernandez, MD, MHS, and colleagues calls for major changes in the research ecosystem to enable pragmatic trials, especially those comparing different treatment

The collaboration will initially focus on projects related to heart failure, coronary and vascular disease, and atrial fibrillation.

The HERO registry, which can be joined at HeroesResearch.org, will enroll thousands of healthcare workers to answer crucial questions about the impact of novel coronavirus on their lives.

The study is the first cardiovascular outcomes trial to compare two different types of cancer treatment.

A DCRI-led study found that using oral anticoagulants, predominantly warfarin, led to increased risk of bleeding and intracranial hemorrhage for patients with atrial fibrillation and end-stage renal disease.

A study led by DCRI and Duke researchers was the first to comprehensively explore skin tone as a potential factor affecting accuracy of heart rate measurements from wearable devices.

The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The award honors Douglas’ work in diversity and inclusion in the field of cardiology.